Evaluation of a novel tumor vaccine in dogs with hemangiosarcoma.

Evaluation of a novel tumor vaccine in dogs with hemangiosarcoma. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Evaluation of a novel tumor vaccine in dogs with hemangiosarcoma. Abstract Text:

Lance W U'Ren,Barbara J Biller,Robyn E Elmslie,Douglas H Thamm,Steven W Dow,

BACKGROUND: Hemangiosarcoma (HSA) is a highly metastatic and often rapidly fatal tumor of dogs. At present, adjuvant chemotherapy is the only proven effective treatment for dogs with HSA, though the benefits from chemotherapy are modest. Administration of immunotherapy together with chemotherapy has also been reported to improve survival in dogs with HSA. Therefore, we evaluated safety and immunologic responses to a novel tumor vaccine administered together with doxorubicin chemotherapy in dogs with different stages of HSA. HYPOTHESIS: That tumor vaccination could be safely and effectively combined with doxorubicin chemotherapy for treatment of dogs with HSA. ANIMALS: Twenty-eight dogs with various stages of HSA were enrolled in the study. METHODS: The HSA vaccine was prepared with lysates of allogeneic canine HSA cell lines mixed with an adjuvant composed of liposome-DNA complexes. Dogs received a series of 8 immunizations administered over a 22-week period, and most also received chemotherapy. Clinical adverse effects were noted, immune responses were measured by enzyme-linked immunosorbent assay (ELISA) and flow cytometry, and survival times were calculated. RESULTS: The most common adverse effects observed in vaccinated dogs also treated with doxorubicin chemotherapy were diarrhea and anorexia. Vaccinated dogs were found to mount strong humoral immune responses against a control antigen and, most dogs also mounted antibody responses against canine HSA cells. Thirteen dogs with stage II splenic HSA that received the tumor vaccine plus doxorubicin chemotherapy had an overall median survival time of 182 days. CONCLUSIONS: We conclude that an allogeneic tumor lysate vaccine is safe in dogs with HSA and can elicit humoral immune responses in dogs that are receiving concurrent doxorubicin chemotherapy.

Evaluation of a novel tumor vaccine in dogs with hemangiosarcoma. Publishing Authors By Initials

LW U'Ren,BJ Biller,RE Elmslie,DH Thamm,SW Dow,

For similar neoplasms: neoplasms by site: splenic neoplasms research abstracts see: neoplasms: neoplasms by site: splenic neoplasms research

PUBMED ID PMID:

MEDLINE DATE:

Evaluation of a novel tumor vaccine in dogs with hemangiosarcoma. Journal Published:

PUBLICATION TYPE: Research Support, N.I.H., Extr

Journal: Journal of veterinary internal medicine / American

VOLUME: 21

Page Numbers: 113-20

Journal Abbreviation: J. Vet. Intern. Med.

ISSN: 0891-6640

DAY: 3

MONTH: 12

YEAR: 2007

Evaluation of a novel tumor vaccine in dogs with hemangiosarcoma. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8708660

Evaluation of a novel tumor vaccine in dogs with hemangiosarcoma. Keywords Mesh Terms:

KEYWORDS: Splenic Neoplasms

MESH TERMS: veterinary

Chemical & Substance for Abstract: Evaluation of a novel tumor vaccine in dogs with hemangiosarcoma. Information

Substance Name: Doxorubicin

Registry Number: 23214-92-8

Grant and Affiliation Information for Evaluation of a novel tumor vaccine in dogs with hemangiosarcoma.

AFFILIATION: Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins 80523, USA.

Country: United States

AGENCY: United States NCRR

GRANT: RR00707

ACRONYM: RR

MEDLINETA: J Vet Intern Med

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Evaluation of a novel tumor vaccine in dogs with hemangiosarcoma Related Publications

• Action potentials of cerebellar cortex in response to local electrical stimulation.
• Carbon monoxide exposure on denali: comparing the 2004 and 2005 climbing seasons.
• Complementary global maps for orientation coding in upper and lower layers of the monkey's foveal striate cortex.
• Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs.
• Corticotropin releasing hormone modulates endotoxin-induced inflammatory cytokine expression in human trophoblast cells.
• Diarrheal disease control studies; conical net for collecting flies.
• Diversification of the Function of Cell-to-Cell Signaling in Regulation of Virulence Within Plant Pathogenic Xanthomonads.
• EXTRINSIC REGULATORY MECHANISMS OF SEIZURE ACTIVITY.
• Evaluation of a novel tumor vaccine in dogs with hemangiosarcoma.
• Evaluation of a xenogeneic VEGF vaccine in dogs with soft tissue sarcoma.
• Excitability of skeletal muscle during development, denervation, and tissue culture.
• Foveal tracking cells in the superior temporal sulcus of the macaque monkey.
• Indications for steroid anaesthesia.
• Infants' early ability to segment the conversational speech signal predicts later language development: a retrospective analysis.
• Integrative physiology, functional genomics and the phenotype gap: a guide for comparative physiologists.
• Interspecies signalling via the Stenotrophomonas maltophilia diffusible signal factor influences biofilm formation and polymyxin tolerance in Pseudomonas aeruginosa.
• Intradural chordoma.
• Liposome-nucleic acid immunotherapeutics.
• Mefloquine-induced disruption of calcium homeostasis in Mammalian cells is similar to that induced by ionomycin.
• Neutrophil function in septic dogs.
• Oxidative stress during acute FIV infection in cats.
• Permanent transvenous dual-chamber pacing using the coronary sinus in a patient with a mechanical prosthetic tricuspid valve.
• Stance dependence of automatic postural adjustments in humans.
• Sustained generation of tissue dendritic cells from cats using organ stromal cell cultures.
• The effect of prolonged veno-arterial pumping on the circulation of the dog.
• The establishment clause argument for choice.
• Treatment of cerebral palsy; clinical study in use of d-tubocurarine in peanut oil and myricin.
• Use of FoxP3 expression to identify regulatory T cells in healthy dogs and dogs with cancer.
• Use of radium in treatment of hypertrophic lymphoid tissue in the nasopharynx.
• Vaccination with liposome--DNA complexes elicits enhanced antitumor immunity.